The short answer: A PARP inhibitor is a targeted medicine, taken as tablets at home, that some women are offered after surgery and chemotherapy for advanced ovarian cancer. Its job is to help keep the cancer from coming back for longer. It suits women whose cancer shrank well with platinum chemotherapy, and it usually helps most when tests show a BRCA gene change or HRD (a weakness in the tumour’s DNA repair). It is not right for everyone. In India it costs about ₹1–3 lakh a month (indicative; ask the hospital for a written estimate), and approvals can differ in India from other countries, so the team confirms which medicine is approved and available for your situation. Families searching in Hindi often write andashay ka cancer (अंडाशय का कैंसर) treatment ke baad tablet.
After surgery and platinum chemotherapy for advanced ovarian cancer, some women are offered maintenance treatment with a PARP inhibitor. Maintenance treatment is intended to delay the cancer from returning or progressing after it has already responded to initial treatment. It is not another operation, and it does not mean chemotherapy failed.
The decision depends on the ovarian-cancer subtype, stage, response to platinum chemotherapy, BRCA1/2 result, homologous recombination deficiency (HRD) result, previous bevacizumab, blood counts, kidney and liver function, side-effect risks, medicine availability and personal priorities. For how these tumour and gene tests guide treatment more widely, see targeted therapy and biomarker testing.
On This Page
Should I Have PARP Inhibitor Maintenance After First Treatment?
A PARP inhibitor may be considered after a complete or partial response to platinum-based chemotherapy, particularly for advanced high-grade epithelial ovarian, fallopian-tube or primary peritoneal cancer. The expected benefit is often greatest when the tumour has a BRCA1/2 mutation or is HRD-positive, but eligibility is not determined by one test alone.
The important questions are:
- What exact type of ovarian cancer do I have?
- Did it respond to platinum chemotherapy?
- What are my germline BRCA, tumour BRCA and HRD results?
- Which maintenance medicine and evidence apply to my situation?
- How large is the likely absolute benefit?
- What side effects, monitoring, cost and treatment duration should I expect?
Observation can still be a reasonable option in some situations. Maintenance should be chosen because its expected benefit justifies its burden, not simply because a tablet exists.
What Is a PARP Inhibitor?
PARP inhibitors are targeted medicines that interfere with how cancer cells repair damaged DNA. PARP stands for poly (ADP-ribose) polymerase, a group of proteins involved in DNA repair. Blocking PARP can make it harder for certain ovarian-cancer cells to survive, particularly when another repair pathway is already defective.
PARP inhibitors are one step within ovarian cancer diagnosis and treatment; they are used after surgery and chemotherapy, not instead of them. Commonly discussed PARP inhibitors in ovarian-cancer care include olaparib and niraparib. Other agents and indications differ by country, regulatory approval and treatment setting. Fuzuloparib is another PARP inhibitor studied extensively in China.
These medicines are usually tablets or capsules taken at home. They are not conventional chemotherapy, but they can still affect bone marrow, energy, digestion and other organs and require regular oncology supervision.
What Do BRCA-Positive, BRCA-Negative and HRD-Positive Mean?
BRCA1 and BRCA2 are genes involved in repairing DNA damage. A harmful change can be inherited—called a germline mutation—or present only in the tumour—called a somatic mutation.
HRD means homologous recombination deficiency. It describes a broader failure in an important DNA-repair pathway. A tumour can be HRD-positive because of a BRCA mutation or another molecular change. A BRCA-negative tumour can therefore still be HRD-positive.
| Result | What it may mean for maintenance | What it does not mean |
|---|---|---|
| Germline BRCA-positive | Often predicts a substantial benefit from an appropriate PARP inhibitor and has implications for blood relatives. | It does not guarantee that maintenance will prevent recurrence. |
| Tumour BRCA-positive only | May also predict PARP-inhibitor benefit, depending on the regimen and setting. | It does not necessarily mean the mutation was inherited. |
| BRCA-negative, HRD-positive | Some maintenance strategies can still provide meaningful benefit. | BRCA-negative does not automatically mean a PARP inhibitor cannot work. |
| HRD-negative or HR-proficient | Benefit may be smaller and the treatment decision requires closer attention to the specific medicine, evidence and toxicity. | It does not mean the cancer will definitely recur or that no maintenance option exists. |
Ask whether both inherited and tumour testing were performed, which laboratory and method were used, and whether the HRD result was conclusive. Genetic counselling is important when a germline mutation is found.
Which Maintenance Options May Be Discussed?
The options depend on the original treatment and biomarker results. They may include:
- a PARP inhibitor alone;
- bevacizumab maintenance in an appropriate patient;
- a PARP inhibitor combined with bevacizumab in a setting supported by the relevant evidence and approval;
- observation with structured follow-up; or
- a clinical trial.
Olaparib has strong first-line maintenance evidence for BRCA-mutated advanced ovarian cancer. Olaparib with bevacizumab has been studied for selected HRD-positive disease after a bevacizumab-containing first-line plan. Niraparib has first-line maintenance evidence across biomarker groups, although the size of benefit and current approved indications must be interpreted for the applicable country and date.
The medicine used for recurrent, platinum-sensitive disease may not be chosen in the same way as first-line maintenance. Previous PARP exposure also affects later treatment decisions.
What Did the Fuzuloparib FZOCUS-1 Study Find?
FZOCUS-1 was a phase 3 trial conducted at 57 centres in China. It enrolled 674 women with newly diagnosed Stage III or IV ovarian, fallopian-tube or primary peritoneal cancer. Participants had responded completely or partially after surgery and six to nine cycles of platinum-based chemotherapy.
Women were assigned to fuzuloparib plus apatinib, fuzuloparib alone or placebo. Median progression-free survival was:
- 26.9 months with fuzuloparib plus apatinib;
- 29.9 months with fuzuloparib alone; and
- 11.1 months with placebo.
Both fuzuloparib groups had longer progression-free survival than placebo, whether or not the woman carried an inherited BRCA change. In women whose tumours were HRD-positive, adding apatinib did not lengthen progression-free survival compared with fuzuloparib alone; in HRD-negative women there was a trend in favour of the combination, but it was not conclusive. The size and certainty of benefit differed between groups.
Overall-survival results were not mature enough to show that women lived longer. The study also does not establish routine availability or regulatory approval in India. It should be understood as important evidence about PARP maintenance, not as a reason to obtain fuzuloparib outside a properly authorised oncology pathway.
What Benefit Can Maintenance Treatment Offer?
Maintenance trials primarily measure progression-free survival: the time before scans, symptoms or other evidence show that cancer has progressed. Delaying progression can postpone further chemotherapy and the problems caused by active cancer.
A progression-free-survival benefit does not automatically prove an overall-survival benefit. Later treatments, crossover, long follow-up and differences in subsequent care can affect overall survival. Quality of life, side effects, cost and time on treatment also matter.
Ask for the likely absolute benefit for a person with your biomarker group and treatment response. A hazard ratio describes differences between groups over time; it is not the percentage chance that an individual patient will remain cancer-free.
What Side Effects Can PARP Inhibitors Cause?
Side effects vary between medicines and patients. Common problems include:
- tiredness or weakness;
- nausea, reduced appetite, constipation or diarrhoea;
- anaemia, low platelets or low white-cell counts;
- headache, dizziness or sleep disturbance;
- changes in kidney or liver blood tests; and
- high blood pressure or palpitations with some regimens.
Dose interruption or reduction is common and does not necessarily mean treatment has failed. The aim is a tolerable dose that can be taken safely.
Rare but serious bone-marrow disorders, including myelodysplastic syndrome and acute myeloid leukaemia, have occurred after PARP-inhibitor treatment. Persistent or worsening low blood counts require investigation rather than repeated treatment without explanation.
Contact the oncology team for fever, unusual bruising or bleeding, severe weakness, breathlessness, chest pain, fainting, persistent vomiting, inability to eat or drink, yellowing of the skin or rapidly worsening symptoms.
How Is PARP Maintenance Monitored?
Before treatment, clinicians review blood counts, kidney and liver function, blood pressure where relevant, previous chemotherapy toxicity, current medicines and pregnancy considerations. Blood tests are usually more frequent early in treatment and then repeated at scheduled intervals.
Monitoring may include:
- complete blood count;
- kidney and liver tests;
- blood pressure and pulse for particular medicines or combinations;
- symptom and side-effect review;
- CA-125 when it was informative for that patient; and
- CT or other imaging at planned intervals or when clinically indicated.
CA-125 alone should not be used to decide whether every symptom is recurrence. Likewise, a stable marker does not remove the need to assess concerning new symptoms.
How Long Is Maintenance Treatment Taken?
Maintenance is often continued for a protocol-defined period, until progression or until unacceptable toxicity, depending on the medicine, treatment setting and response. Some first-line regimens use a fixed maximum duration when there is no evidence of disease, while other settings may continue differently.
Do not copy another patient’s treatment length. Ask the oncologist to write down:
- the planned start date and maximum duration;
- what counts as progression;
- which side effects trigger a pause, lower dose or permanent stop;
- what happens if tablets are missed; and
- the follow-up plan after maintenance ends.
When Might a PARP Inhibitor Not Be Suitable?
A different approach may be needed when the cancer did not respond to platinum chemotherapy, the histological subtype or stage does not match the evidence, blood counts have not recovered, severe kidney or liver impairment changes safe dosing, pregnancy is possible, or previous treatment caused a serious PARP-related reaction.
Expected benefit may also be small enough that observation is preferred, particularly after considering HRD status, residual toxicity, other illnesses, medicine cost and quality of life. This is an individual treatment decision, not a failure to pursue care aggressively.
Questions to Ask Before Starting Maintenance
- What exact cancer type, stage and treatment response do I have?
- What are my germline BRCA, tumour BRCA and HRD results?
- Which PARP inhibitor or alternative are you recommending, and why?
- How much absolute progression-free benefit is expected in my biomarker group?
- Has this treatment shown an overall-survival or quality-of-life benefit?
- What is approved and reliably available in India for my indication?
- How often will blood tests, blood pressure checks and scans be needed?
- Which side effects should prompt a same-day call?
- How are dose reductions handled?
- How long is treatment planned?
- What are the total medicine and monitoring costs?
- What follow-up would I receive if I choose observation?
Frequently Asked Questions
Is maintenance therapy the same as chemotherapy?
PARP inhibitors are targeted medicines rather than conventional chemotherapy. They are used after the initial cancer has responded, but they can still cause significant side effects and require monitoring.
Does BRCA-negative mean a PARP inhibitor cannot work?
No. Some BRCA-negative tumours are HRD-positive, and some trials have shown benefit beyond BRCA-mutated disease. The expected benefit may be smaller and depends on the particular medicine and setting.
Does BRCA-positive mean maintenance will definitely prevent recurrence?
No. BRCA mutations often predict greater benefit, but maintenance reduces risk across groups; it cannot guarantee that cancer will not return.
Is fuzuloparib available in India?
Fuzuloparib has strong trial evidence and regulatory use in China, but routine Indian availability and approval for a specific indication must be verified through current official and hospital channels. Do not purchase an unverified imported product.
Why might my PARP-inhibitor dose be reduced?
A lower dose may be needed for low blood counts, fatigue, nausea, organ-function changes or other toxicity. Dose adjustment is a standard safety strategy and does not automatically remove treatment benefit.
Can ovarian cancer return while taking maintenance?
Yes. Maintenance delays progression for many patients but cannot prevent every recurrence. New symptoms and scheduled assessments remain important.
How much does PARP inhibitor treatment cost in India?
As a rough guide, PARP-inhibitor tablets cost about ₹1–3 lakh a month in India. This is indicative only. The total depends on the medicine and dose, how many months it is taken, blood tests and scans, and any insurance or government-scheme cover. If bevacizumab is part of the plan, it is estimated separately at about ₹4–8 lakh. Ask the hospital for a written estimate before starting, and ask whether the medicine is approved and reliably available in India for your situation.
What is an HRD test, and do I need one?
An HRD (homologous recombination deficiency) test is done on tumour tissue from surgery or a biopsy. It checks whether the cancer has a weakness in repairing its DNA, which can make PARP inhibitors work better. It is one of several results the team weighs, together with BRCA testing, how the cancer responded to chemotherapy and your general health. A negative result does not by itself rule out every maintenance option.
Will I lose my hair on a PARP inhibitor?
Major hair loss is not typical with PARP-inhibitor tablets, unlike the carboplatin–paclitaxel chemotherapy given earlier. Hair lost during chemotherapy usually grows back. Tell the team if you notice unusual thinning or any new side effect.
Can I become pregnant while taking a PARP inhibitor?
PARP inhibitors can harm a developing baby. Discuss contraception, fertility and pregnancy plans before treatment and follow the medicine-specific guidance after the final dose.
Related Guidance and Medical Sources
Read the complete ovarian-cancer treatment guide, learn about chemotherapy, or request a gynaecological cancer second opinion.